Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
As an addition to the social responsibility project it started for sheltering street animals, the lucky address for shopping, n11.com, has now redesigned its delivery boxes, turning them into portable "homes" that can protect animals living on the streets from the harsh conditions of winter.
Contributing to the e-trade sector with its innovative activities, n11.com has completed the design work that it has been conducting in the last period, turning its delivery boxes into portable "homes" for street animals.
The special boxes were designed to especially endure cold weather conditions and were produced after approximately a year of Research and Development efforts. From now on, shoppers who order pet food on n11.com will be contributing to providing street dogs and cats with a warm home.
To view the multimedia release go to:
http://www.multivu.com/players/English/7664151-n11-com-boxes-homes-animals/
Internationally renowned restaurant, MR CHOW, is now open at Caesars Palace. The Las Vegas location is the seventh of the luxurious Beijing cuisine eatery, joining the ranks of notable hot spots in Miami, Malibu, New York City, Beverly Hills and the original location in London. From the moment guests arrive, MR CHOW will entertain and inspire, from the unparalleled design to the impeccable service to the notable cuisine.
“This union between Caesars Palace and MR CHOW is a dream come true,” said founder Michael Chow.
“We look forward to our guests experiencing MR CHOW as the culinary empire and reputation of Caesars Palace continues to grow,” said Gary Selesner, Caesars Palace regional president. “MR CHOW’s elevated Chinese cuisine and chic atmosphere perfectly complements the impressive culinary collection of celebrity-chef helmed restaurants of Bobby Flay, Gordon Ramsay, Nobu Matsuhisa, Guy Savoy and more. As we enter our 50th golden anniversary year at Caesars Palace, we continue to strive to delight our guests at the dining table, while contributing to the world renowned dining scene in Las Vegas.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7719251-caesars-palace-mr-chow/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
